Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
13.1M
-
Number of holders
-
164
-
Total 13F shares, excl. options
-
15.9M
-
Shares change
-
+539K
-
Total reported value, excl. options
-
$947M
-
Value change
-
+$8.08M
-
Put/Call ratio
-
0.93
-
Number of buys
-
109
-
Number of sells
-
-71
-
Price
-
$59.64
Significant Holders of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) as of Q3 2017
214 filings reported holding EGRX - EAGLE PHARMACEUTICALS, INC. - Common Stock as of Q3 2017.
EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) has 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.9M shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (1.81M shares), BlackRock Inc. (1.26M shares), VICTORY CAPITAL MANAGEMENT INC (978K shares), STATE STREET CORP (975K shares), Hudson Executive Capital LP (971K shares), Park West Asset Management LLC (908K shares), IRIDIAN ASSET MANAGEMENT LLC/CT (814K shares), First Eagle Investment Management, LLC (602K shares), VANGUARD GROUP INC (566K shares), and JW Asset Management, LLC (526K shares).
This table shows the top 164 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.